-

Aptar Declares Quarterly Dividend and Announces 2021 Annual Meeting Details

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, today declared a quarterly cash dividend of $0.36 per share. The payment date is February 17, 2021, to stockholders of record as of January 27, 2021.

As previously announced, Aptar will hold a conference call on Friday, February 19, 2021 at 8:00 a.m. Central Time to discuss the Company’s fourth quarter and year-end results for 2020. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website.

Annual Meeting

The Board also announced that the 2021 Annual Meeting of Stockholders will be held virtually on May 5, 2021, at 9:00 a.m. Central Time. The record date for stockholders entitled to vote at the meeting is March 12, 2021. More details regarding accessing the meeting will be shared as we get closer to the event.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active packaging solutions. Aptar uses insights, design, engineering and science to create dosing, dispensing and protective packaging technologies for the world’s leading brands, in turn making a meaningful difference in the lives, looks, health and homes of millions of people around the world. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated employees in 19 countries. For more information, visit www.aptar.com.

Contacts

Investor Relations Contact:
Matt DellaMaria
matt.dellamaria@aptar.com
815-479-5530

Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

AptarGroup, Inc.

NYSE:ATR

Release Versions

Contacts

Investor Relations Contact:
Matt DellaMaria
matt.dellamaria@aptar.com
815-479-5530

Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

More News From AptarGroup, Inc.

Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring...

Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026...

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhyt...
Back to Newsroom